Brukinsa®
zanubrutinib 160 mg tablets

NEW BRUKINSA TABLETS FREQUENTLY ASKED QUESTIONS FOR PATIENTS

BRUKINSA capsules are being replaced by BRUKINSA tablets. Continue reading for answers to Frequently Asked Questions.

INDICATIONS

BRUKINSA is a type of targeted oral therapy called a Bruton's tyrosine kinase (BTK) inhibitor.

BRUKINSA is a prescription medicine used to treat adults with:

- Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
- Waldenström's macroglobulinemia (WM).
- Mantle cell lymphoma (MCL) who have received at least one prior treatment for their cancer.
- Marginal zone lymphoma (MZL) when the disease has come back or did not respond to treatment and who have received at least one certain type of treatment.
- Follicular lymphoma (FL), in combination with the medicine obinutuzumab, when the disease has come back or did not respond to treatment and who have received at least two prior treatments.

BRUKINSA was approved for MCL, MZL, and FL based on response rate. There are ongoing evaluations to confirm clinical benefit for these uses.

It is not known if BRUKINSA is safe and effective in children.

Please see additional Important Safety Information throughout and accompanying full Patient Information.

What are the benefits of the BRUKINSA tablet?

New BRUKINSA tablets:

- Reduce the number of pills you have to take daily from 4 to 2
- Are smaller in size than the capsules
- Have a film coating, making them easy to swallow
- Can continue to be prescribed once or twice daily by your doctor

What is the difference between BRUKINSA capsules and tablets?

BRUKINSA 80 mg capsules require you to take 4 capsules daily, while the new BRUKINSA 160 mg tablets require only 2 tablets daily, reducing the number of pills by 50%. As an added feature, BRUKINSA tablets are significantly smaller than the capsules, with a film coating, making them easier to swallow. The recommended daily dose of BRUKINSA remains 320 mg.

BRUKINSA capsules	**BRUKINSA tablets**
4 x 80 mg capsules	2 x 160 mg tablets



IMPORTANT SAFETY INFORMATION (continued)

BRUKINSA may cause serious side effects, including:

Bleeding problems (hemorrhage). Bleeding problems are common with BRUKINSA, and can be serious and may lead to death. Your risk of bleeding may increase if you are also taking a blood thinner medicine. Tell your healthcare provider if you have any signs or symptoms of bleeding, including: blood in your stools or black stools (looks like tar), pink or brown urine, unexpected bleeding, or bleeding that is severe or you cannot control, vomit blood or vomit that looks like coffee grounds, cough up blood or blood clots, increased bruising, dizziness, weakness, confusion, change in speech, or headache that lasts a long time.

Infections that can be serious and may lead to death. Tell your healthcare provider right away if you have fever, chills, or flu-like symptoms.

Heart rhythm problems (atrial fibrillation, atrial flutter, and ventricular arrhythmias) that can be serious and may lead to death. Tell your healthcare provider if you have any of the following signs or symptoms: your heartbeat is fast or irregular, feel lightheaded or dizzy, pass out (faint), shortness of breath, or chest discomfort.

Are there any changes to the BRUKINSA dose or schedule?

- No. Continue to take BRUKINSA tablets either once or twice daily
- The recommended dose of BRUKINSA is 320 mg daily, which is two 160 mg tablets
- For patients with follicular lymphoma (FL), tablets will continue to be dosed in combination with obinutuzumab
- Talk to your doctor about dosing options that can be tailored to your schedule

ONCE A DAY for convenience	OR	**TWICE A DAY** to match the schedule of other medicines you may take
		AM  PM 
2 tablets taken once daily		1 tablet in the morning, 1 later in the day

Dosing schedule for BRUKINSA + obinutuzumab in FL



IMPORTANT SAFETY INFORMATION (continued)

BRUKINSA may cause serious side effects, including:

Decrease in blood cell counts (white blood cells, platelets, and red blood cells). Your healthcare provider should do blood tests during treatment with BRUKINSA to check your blood counts.

Please see additional Important Safety Information throughout and accompanying full Patient Information.

Brukinsa® zanubrutinib 160 mg tablets

How should BRUKINSA tablets be taken?

BRUKINSA tablets:

- Should be taken with water
- Can be taken with or without food
- Should not be chewed or crushed
- Can be split in half as needed

If you miss a dose of BRUKINSA, you should take it as soon as you remember. Try to take it on the same day. Return to your normal schedule the next day.

Tell your doctor about all the medications you are currently taking, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Can BRUKINSA capsules and tablets be taken together?

No. BRUKINSA capsules are being replaced by BRUKINSA tablets and should not be taken together. Use up your remaining capsules and then switch to taking tablets. If you think you have taken too much BRUKINSA, contact your doctor or poison control immediately, even if there are no signs or symptoms.

Are the 160 mg tablets bigger and/or harder to swallow?

No, the tablets are about one-third smaller in length than the capsules, so they should be easier to swallow.

Will BRUKINSA capsules still be available?

No, BRUKINSA capsules are being replaced by BRUKINSA tablets and should not be taken together. Use up your remaining capsules and then switch to taking tablets.

Are new prescriptions required for BRUKINSA tablets?

Yes, but your doctor will send the new prescription directly to your pharmacy, so the transition should be seamless.

Will BRUKINSA tablets be available through the same pharmacies?

Yes. Access to BRUKINSA tablets will be available through the same sources.

Are the efficacy and safety of BRUKINSA tablets the same as the capsule formulation?

BRUKINSA tablets are expected to have the same efficacy and safety as BRUKINSA capsules, based on trials that studied how the tablets work in the body.

IMPORTANT SAFETY INFORMATION (continued)

BRUKINSA may cause serious side effects, including:

Liver problems. Liver problems, which may be severe or life-threatening, or lead to death, can happen in people treated with BRUKINSA. Your healthcare provider will do blood tests to check your liver before and during treatment with BRUKINSA. Tell your healthcare provider or get medical help right away if you have any signs of liver problems, including stomach pain or discomfort, dark-colored urine, or yellow skin and eyes.

IMPORTANT SAFETY INFORMATION (continued)

BRUKINSA may cause serious side effects, including:

Second primary cancers. New cancers have happened in people during treatment with BRUKINSA, including cancers of the skin or other organs. Your healthcare provider will check you for other cancers during treatment with BRUKINSA. Use sun protection when you are outside in sunlight.

Please see additional Important Safety Information throughout and accompanying full Patient Information.

Brukinsa® zanubrutinib 160 mg tablets

There are fewer tablets in a bottle than there are capsules in a carton, so will there be changes to the frequency of prescription refills required?

No. BRUKINSA will continue to be prescribed as a 30-day supply.

Will the tablets need to be stored any differently than the capsules?

Storage recommendations remain unchanged. Store tablets at 68°F to 77°F (20°C to 25°C).

What changes have been made to the BRUKINSA tablet packaging compared with the capsules?

BRUKINSA will continue to come in a 30-day supply bottle with a child-resistant cap.

NOTES

myBeOneSupport™

Patient Assistance Program

We want you to focus on your treatment and day-to-day living.

To help meet your needs, myBeOne Support pairs eligible patients with a dedicated Oncology Nurse Advocate who can help personalize support throughout your treatment with BRUKINSA.

Program services include:

Simplifying access to BRUKINSA

Educating you and your caregivers about your treatment and disease

Connecting you and your caregivers to independent organizations that may be able to assist with day-to-day living support

Independent third-party organizations have their own rules for eligibility. BeOne Medicines has no involvement in their decision-making or eligibility criteria. This information is non-exhaustive and not meant as an endorsement from BeOne Medicines.

For any questions, or to help you get started, call 1-833-234-4363, M-F 8 AM-8 PM ET, or visit myBeOneSupport.com.

BRUKINSA, BeOne Medicines, and myBeOneSupport are trademarks owned by BeOne Medicines I GmbH or its affiliates.

myBeOneSupport™ is not insurance and does not guarantee product coverage or reimbursement.

© BeOne Medicines I GmbH, 2025 All Rights Reserved.
0525-BRU-PRC-272 6/2025

Brukinsa® zanubrutinib 160 mg tablets